Maravai LifeSciences Holdings Inc. (MRVI) Financial Statements (2025 and earlier)

Company Profile

Business Address 10770 WATERIDGE CIRCLE SUITE 200
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments322,399574,962632,138551,272
Cash and cash equivalent322,399574,962632,138551,272
Receivables38,52054,605138,624117,512
Inventory, net of allowances, customer advances and progress billings50,08251,39743,15251,557
Inventory50,08251,39743,15251,557
Other undisclosed current assets18,14518,94833,98819,698
Total current assets:429,146699,912847,902740,039
Noncurrent Assets
Property, plant and equipment   52,69446,332
Intangible assets, net (including goodwill)354,835547,016500,331270,337
Goodwill159,878326,029283,668152,766
Intangible assets, net (excluding goodwill)194,957220,987216,663117,571
Deferred income tax assets   765,799808,117
Other noncurrent assets59,78977,622115,58953,451
Other undisclosed noncurrent assets164,474162,900  
Total noncurrent assets:579,098787,5381,434,4131,178,237
TOTAL ASSETS:1,008,2441,487,4502,282,3151,918,276
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities36,40760,23759,36242,728
Accounts payable  5,9918,154
Accrued liabilities36,40760,23753,37134,574
Deferred revenue2,3753,3603,08810,211
Debt6,2326,0735,4406,000
Due to related parties✕✕✕42,25434,838
Other undisclosed current liabilities 11,95717,798  
Total current liabilities:56,97187,468110,14493,777
Noncurrent Liabilities
Long-term debt and lease obligation321,598550,604521,997524,591
Long-term debt, excluding current maturities290,492518,707521,997524,591
Finance lease, liability31,10631,897  
Liabilities, other than long-term debt52,46659,494744,931754,547
Deferred income tax liabilities    
Due to related parties✕✕✕675,956713,481
Other liabilities52,46659,49468,97541,066
Total noncurrent liabilities:374,064610,0981,266,9281,279,138
Total liabilities:431,035697,5661,377,0721,372,915
Equity
Equity, attributable to parent, including:325,292416,753545,218315,499
Additional paid in capital181,874128,503137,898128,386
Accumulated other comprehensive income    
Retained earnings140,891285,737404,766184,561
Other undisclosed equity, attributable to parent2,5272,5132,5542,552
Equity, attributable to noncontrolling interest251,917373,131360,025229,862
Total equity:577,209789,884905,243545,361
TOTAL LIABILITIES AND EQUITY:1,008,2441,487,4502,282,3151,918,276

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenues259,185288,945883,001799,240
Cost of revenue(150,876)(148,743)(168,957)(140,561)
Gross profit:108,309140,202714,044658,679
Operating expenses(345,929)(175,136)(147,628)(104,034)
Other undisclosed operating income2,0033,2867,800 
Operating income (loss):(235,617)(31,648)574,216554,645
Nonoperating income25,06226,3901,980279
Investment income, nonoperating27,40327,7272,338 
Other nonoperating income (expense)(2,341)(1,337)(358)279
Interest and debt expense(50,887)(45,892)(20,622)(30,260)
Income (loss) from continuing operations before equity method investments, income taxes:(261,442)(51,150)555,574524,664
Other undisclosed income (loss) from continuing operations before income taxes(40)668,886(4,102)6,101
Income (loss) from continuing operations before income taxes:(261,482)617,736551,472530,765
Income tax expense (benefit)1,860(756,111)(60,809)(61,515)
Income (loss) from continuing operations:(259,622)(138,375)490,663469,250
Income before gain (loss) on sale of properties:✕✕✕✕469,250
Net income (loss):(259,622)(138,375)490,663469,250
Net income (loss) attributable to noncontrolling interest114,77619,346(270,458)(287,213)
Net income (loss) available to common stockholders, basic:(144,846)(119,029)220,205182,037
Dilutive securities, effect on basic earnings per share   87132
Other undisclosed net income available to common stockholders, diluted   205,984220,187
Net income (loss) available to common stockholders, diluted:(144,846)(119,029)426,276402,356

Comprehensive Income ($ in thousands)
Annual | Quarterly

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Net income (loss):(259,622)(138,375)490,663469,250
Other undisclosed comprehensive income   55
Comprehensive income (loss):(259,622)(138,375)490,663469,305
Comprehensive income (loss), net of tax, attributable to noncontrolling interest114,77619,346(270,458)(287,224)
Comprehensive income (loss), net of tax, attributable to parent:(144,846)(119,029)220,205182,081

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: